<DOC>
	<DOCNO>NCT02787317</DOCNO>
	<brief_summary>Prolonging infusion may decrease myocardial damage associate bivalirudin use primary PCI . The investigator hypothesize continue bivalirudin infusion commence procedure PCI recommend dose 4 hour would prevent myocardial damage .</brief_summary>
	<brief_title>Bivalirudin Stable Ischemic Heart Disease Patients Undergoing PCI</brief_title>
	<detailed_description>Bivalirudin widely use anticoagulant percutaneous coronary intervention ( PCI ) coronary heart disease . Prolonging infusion may decrease myocardial damage associate bivalirudin use primary PCI . However , whether prolong infusion bivalirudin could prevent ischemic complication unknown . The investigator examine effect prolong drug infusion elective PCI . The investigator hypothesize continue bivalirudin infusion commence procedure PCI recommend dose 4 hour would prevent myocardial damage .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients age 18 80 year stable ischemic heart disease PCI require . cardiogenic shock ; thrombolytic therapy administer randomization anticoagulant administer within 48 hour randomization ; active recent major bleed bleed predisposition ; major surgery within 1 month ; clinical syndrome suspicious aortic dissection , pericarditis , endocarditis ; blood pressure high 180/110 mm Hg ; know hemoglobin le 10 g/dL , platelet count le 100 × 109/L , aminotransferase level great 3 × upper limit normal , creatinine clearance le 30 mL/min ; history heparininduced thrombocytopenia ; allergy study drug device ; pregnancy lactation ; condition make PCI unsuitable might interfere study adherence ; patient unwilling unable provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>bivalirudin</keyword>
	<keyword>myocardial injure</keyword>
</DOC>